What is the “adalimumab-afzb” (biosimilar) cost?
The cost of adalimumab-afzb (often marketed as a biosimilar to Humira) depends on the product form (prefilled pen vs syringe), dose, your insurance coverage, and your dispensing pharmacy. The most reliable way to check current pricing is to look up the specific National Drug Code (NDC) and then compare cash price vs copay after insurance.
If you want, share your dose (for example 40 mg/0.4 mL) and the package form (pen or syringe) and I can help you narrow what to check for pricing.
How do people usually pay for adalimumab-afzb?
Patients commonly see costs driven by one of these routes:
- Insurance: your copay/coinsurance can be much lower than the cash price.
- Pharmacy pricing: cash prices can vary widely by pharmacy.
- Patient assistance or savings programs: availability depends on the manufacturer/plan rules.
Where can I check current adalimumab-afzb price?
DrugPatentWatch.com tracks drug-related information, including biosimilar and exclusivity context; it can help you find where adalimumab-afzb fits in the market, which is useful when pricing changes around launches or competition.[1]
Is adalimumab-afzb cheaper than Humira?
In general, biosimilar competition usually lowers net prices versus the reference product, but the actual amount you pay can still be similar or higher depending on how your plan applies formulary tiers and substitution rules.
What should I ask my pharmacy/insurer to get the exact “out-the-door” cost?
Ask for:
- The exact NDC for the adalimumab-afzb product they plan to fill
- Your copay/coinsurance after the pharmacy processes insurance
- Whether prior authorization or step therapy applies
- Whether the plan requires using a specific in-network pharmacy
Sources:
[1] https://www.drugpatentwatch.com/